A2P Stock Overview
Provides products, services, and IT solutions for surgery, diagnostic imaging, and nuclear medicine applications in Poland.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Synektik Spólka Akcyjna Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł31.45 |
| 52 Week High | zł35.95 |
| 52 Week Low | zł26.00 |
| Beta | 1.2 |
| 11 Month Change | -1.41% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 17.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| A2P | DE Healthcare Services | DE Market | |
|---|---|---|---|
| 7D | 6.6% | -1.8% | -0.5% |
| 1Y | n/a | -27.4% | 1.6% |
Return vs Industry: Insufficient data to determine how A2P performed against the German Healthcare Services industry.
Return vs Market: Insufficient data to determine how A2P performed against the German Market.
Price Volatility
| A2P volatility | |
|---|---|
| A2P Average Weekly Movement | 6.7% |
| Healthcare Services Industry Average Movement | 3.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: A2P has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine A2P's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 164 | Cezary Kozanecki | www.synektik.com.pl |
Synektik Spólka Akcyjna provides products, services, and IT solutions for surgery, diagnostic imaging, and nuclear medicine applications in Poland. The company sells medical equipment used in diagnostics and therapy, and nuclear medicine. It is also involved in development of IT solutions used in radiology, as well as researches, produces, and sells radiopharmaceutical products used in diagnostics for oncology.
Synektik Spólka Akcyjna Fundamentals Summary
| A2P fundamental statistics | |
|---|---|
| Market cap | €291.27m |
| Earnings (TTM) | €17.69m |
| Revenue (TTM) | €138.36m |
16.0x
P/E Ratio2.0x
P/S RatioIs A2P overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A2P income statement (TTM) | |
|---|---|
| Revenue | zł596.39m |
| Cost of Revenue | zł420.01m |
| Gross Profit | zł176.39m |
| Other Expenses | zł100.14m |
| Earnings | zł76.24m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 06, 2024
| Earnings per share (EPS) | 8.94 |
| Gross Margin | 29.58% |
| Net Profit Margin | 12.78% |
| Debt/Equity Ratio | 0% |
How did A2P perform over the long term?
See historical performance and comparison